Clinical Trial Update: Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating artesunate for preemptive treatment of cytomegalovirus infection in stem cell transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• Artesunate (artesunate)

Snippet

Sponsor: Hadassah Medical Organization | Conditions: Cytomegalovirus Infections | Phase 3 | Status: COMPLETED